Improving treatment for liposarcoma by understanding drug resistance
Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance
This study is looking to help patients with dedifferentiated liposarcoma by finding better ways to use a cancer treatment called CDK4/6 inhibitors, especially for those who don’t respond well to it, by testing a combination of two drugs, palbociclib and mirdametinib, to see if it can improve their treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11228162 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of CDK4/6 inhibitors, a type of cancer therapy, specifically for patients with dedifferentiated liposarcoma. The study aims to understand why some patients develop resistance to these drugs and how to overcome it through combination therapies. By analyzing the biological processes involved in cellular senescence and resistance, researchers will conduct a clinical trial to evaluate the efficacy of combining palbociclib with another drug, mirdametinib. This approach seeks to improve treatment outcomes for patients who may not respond well to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with dedifferentiated liposarcoma who are undergoing treatment with CDK4/6 inhibitors.
Not a fit: Patients with other types of cancer or those who do not have dedifferentiated liposarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with liposarcoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using CDK4/6 inhibitors for liposarcoma, indicating that this approach may build on existing knowledge and success.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Tap, William D. — Sloan-Kettering Inst Can Research
- Study coordinator: Tap, William D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.